\u200bThe UK retains strong relations with the Kurdistan Region of Iraq (KRI). British Ministers and officials regularly engage with KRI representatives. On 1 September our Ambassador to Iraq met the KRI Prime Minister, Masrour Barzani, to discuss latest developments and I spoke to the KRI President, Nechirvan Barzani, on 12 June. The UK also provides significant support to the KRI, including through training assistance to the Peshmerga, humanitarian aid, advice on economic reform, and continued efforts to deepen UK-KRI trade.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/1466", "label" : {"_value" : "Biography information for Dr Andrew Murrison"} } , "answeringMemberConstituency" : {"_value" : "South West Wiltshire"} , "answeringMemberPrinted" : {"_value" : "Dr Andrew Murrison"} , "dateOfAnswer" : {"_value" : "2019-09-09", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-09-09T14:10:33.163Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "16"} , "answeringDeptShortName" : {"_value" : "Foreign and Commonwealth Office"} , "answeringDeptSortName" : {"_value" : "Foreign and Commonwealth Office"} , "date" : {"_value" : "2019-09-03", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Iraq: Kurds"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Foreign and Commonwealth Affairs, what assessment he has made of bilateral relations with the Kurdistan region in Iraq; and if he will make a statement.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4126", "label" : {"_value" : "Biography information for Mary Glindon"} } , "tablingMemberConstituency" : {"_value" : "North Tyneside"} , "tablingMemberPrinted" : [{"_value" : "Mary Glindon"} ], "uin" : "286228"} , {"_about" : "http://data.parliament.uk/resources/1144469", "AnsweringBody" : [{"_value" : "Home Office"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1144469/answer", "answerText" : {"_value" : "
It has not proved possible to respond to the hon. Member in the time available before Prorogation.<\/p>
<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4455", "label" : {"_value" : "Biography information for Seema Kennedy"} } , "answeringMemberConstituency" : {"_value" : "South Ribble"} , "answeringMemberPrinted" : {"_value" : "Seema Kennedy"} , "dateOfAnswer" : {"_value" : "2019-09-09", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-09-09T16:23:34.783Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "1"} , "answeringDeptShortName" : {"_value" : "Home Office"} , "answeringDeptSortName" : {"_value" : "Home Office"} , "date" : {"_value" : "2019-09-03", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Visas: Iraq"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for the Home Department, what plans she has to improve the visa application system in the Kurdistan Region of Iraq.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4126", "label" : {"_value" : "Biography information for Mary Glindon"} } , "tablingMemberConstituency" : {"_value" : "North Tyneside"} , "tablingMemberPrinted" : [{"_value" : "Mary Glindon"} ], "uin" : "286229"} , {"_about" : "http://data.parliament.uk/resources/1142923", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1142923/answer", "answerText" : {"_value" : "
It has not proved possible to respond to the hon. Member in the time available before Prorogation.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} , "dateOfAnswer" : {"_value" : "2019-09-09", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-09-09T17:30:47.47Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-09-02", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what assessment he has made of the effect of scrapping Medicines Usage Reviews on people who take multiple medications.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4126", "label" : {"_value" : "Biography information for Mary Glindon"} } , "tablingMemberConstituency" : {"_value" : "North Tyneside"} , "tablingMemberPrinted" : [{"_value" : "Mary Glindon"} ], "uin" : "284398"} , {"_about" : "http://data.parliament.uk/resources/1142924", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1142924/answer", "answerText" : {"_value" : "
Medicines Usage Reviews (MURs) are adherence centred reviews with the community pharmacist in isolation from the prescriber. The new Structured Medication Reviews, offered by clinical pharmacists working in primary care networks (PCNs), will provide a more comprehensive review of a patient\u2019s medication with access to the patient record and with the greater ability of clinical pharmacists to make independent decisions to change medication, if that is the result of a review. It is expected that community pharmacists and practice-based pharmacists will work closely together to optimise medicines usage.<\/p>
Recently announced changes to the Community Pharmacy Contractual Framework, include a Medicines Reconciliation Service, through which community pharmacists will be expected to collaborate with PCN pharmacists and prescribers, to ensure patients are clear about changes to their medicines, post-discharge, in line with the National Institute for Health and Care Excellence guideline on medicines optimisation. The Pharmacy Quality Scheme and the general practice Quality and Outcomes Framework Quality Improvement modules incentivise PCNs and community pharmacy to identify those taking high risk medicines and take actions to reduce risks where appropriate.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} , "dateOfAnswer" : {"_value" : "2019-09-09", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-09-09T15:31:26.97Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-09-02", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "NHS: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what alternative arrangements will be introduced in the new local pharmacy contract to safeguard people taking multiple medications and ensure they receive a regular review of their medication to prevent contraindications.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4126", "label" : {"_value" : "Biography information for Mary Glindon"} } , "tablingMemberConstituency" : {"_value" : "North Tyneside"} , "tablingMemberPrinted" : [{"_value" : "Mary Glindon"} ], "uin" : "284342"} , {"_about" : "http://data.parliament.uk/resources/1142925", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1142925/answer", "answerText" : {"_value" : "
I refer the hon. Member to the answers the then Minister of State for Health (Stephen Hammond MP) gave on 4 July 2019 to Questions 271535<\/a> and 271536<\/a>.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4021", "label" : {"_value" : "Biography information for Chris Skidmore"}
}
, "answeringMemberConstituency" : {"_value" : "Kingswood"}
, "answeringMemberPrinted" : {"_value" : "Chris Skidmore"}
, "dateOfAnswer" : {"_value" : "2019-09-09", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "284346"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-09-09T18:54:26.067Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-09-02", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "NHS: Staff"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to ensure specialist posts such as Parkinson\u2019s nurses are included in the forthcoming NHS workforce plan.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4126", "label" : {"_value" : "Biography information for Mary Glindon"}
}
, "tablingMemberConstituency" : {"_value" : "North Tyneside"}
, "tablingMemberPrinted" : [{"_value" : "Mary Glindon"}
], "uin" : "284401"}
, {"_about" : "http://data.parliament.uk/resources/1142926", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1142926/answer", "answerText" : {"_value" : " I refer the hon. Member to the answers the then Minister of State for Health (Stephen Hammond MP) gave on 4 July 2019 to Questions 271535<\/a> and 271536<\/a>.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4021", "label" : {"_value" : "Biography information for Chris Skidmore"}
}
, "answeringMemberConstituency" : {"_value" : "Kingswood"}
, "answeringMemberPrinted" : {"_value" : "Chris Skidmore"}
, "dateOfAnswer" : {"_value" : "2019-09-09", "_datatype" : "dateTime"}
, "groupedQuestionUIN" : {"_value" : "284401"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-09-09T18:54:26.13Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-09-02", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "NHS: Vacancies"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps the NHS will take as part of the forthcoming NHS workforce plan to minimise the vacancy rates of (a) Parkinson\u2019s nurses and (b) other specialist posts.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4126", "label" : {"_value" : "Biography information for Mary Glindon"}
}
, "tablingMemberConstituency" : {"_value" : "North Tyneside"}
, "tablingMemberPrinted" : [{"_value" : "Mary Glindon"}
], "uin" : "284346"}
, {"_about" : "http://data.parliament.uk/resources/1143006", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1143006/answer", "answerText" : {"_value" : " This data has been extracted from the relevant editions of the National Statistics: \u2018General Pharmaceutical Services\u2019 for England, which is published on an annual basis by NHS Digital and compares a rolling 10 years data:<\/p> <\/p> 2005/06: 148,195<\/p> 2006/07: 559,315<\/p> 2007/08: 951,358<\/p> 2008/09: 1,397,319<\/p> 2009/10: 1,707,139<\/p> 2010/11: 2,108,604<\/p> 2011/12: 2,434,128<\/p> 2012/13: 2,820,415<\/p> 2013/14: 3,081,108<\/p> 2014/15: 3,183,094<\/p> 2015/16: 3,313,309<\/p> 2016/17: 3,368,005<\/p> 2017/18: 3,381,441<\/p> 2018/19: Not yet published<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
}
, "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
, "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
, "dateOfAnswer" : {"_value" : "2019-09-09", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-09-09T15:17:11.817Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-09-02", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "NHS: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, how many Medicines Usage Reviews have taken place in each year since their introduction.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4126", "label" : {"_value" : "Biography information for Mary Glindon"}
}
, "tablingMemberConstituency" : {"_value" : "North Tyneside"}
, "tablingMemberPrinted" : [{"_value" : "Mary Glindon"}
], "uin" : "284562"}
, {"_about" : "http://data.parliament.uk/resources/1143007", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1143007/answer", "answerText" : {"_value" : " Since 2014, community pharmacy contractors have been required to conduct 70% of the Medicines Use Reviews (MURs) that they undertake on the following target groups and data is collected accordingly:<\/p> - Patients taking high-risk medicines (Non-steroidal anti-inflammatory drugs, anticoagulants, antiplatelets and diuretics);<\/p> - Patients recently discharged from hospital;<\/p> - Patients prescribed a respiratory drug, as specified; and<\/p> - Patients regularly prescribed four or more medicines, at least one of which is for a risk of cardiovascular disease, as specified.<\/p> Specific data is not collected on the remaining 30% and so it is not possible to say how many people taking medicines for Parkinson\u2019s disease have received an MUR.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
}
, "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
, "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
, "dateOfAnswer" : {"_value" : "2019-09-09", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-09-09T15:14:49.37Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-09-02", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "Parkinson's Disease: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, how many Medicines Usage Reviews have been undertaken for people with Parkinson's in each year since their introduction.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4126", "label" : {"_value" : "Biography information for Mary Glindon"}
}
, "tablingMemberConstituency" : {"_value" : "North Tyneside"}
, "tablingMemberPrinted" : [{"_value" : "Mary Glindon"}
], "uin" : "284564"}
, {"_about" : "http://data.parliament.uk/resources/1143008", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"}
], "answer" : {"_about" : "http://data.parliament.uk/resources/1143008/answer", "answerText" : {"_value" : " In line with other measures around releasing sensitive data in internal Impact Assessments, the final Impact Assessment produced in July 2019 in respect of the new Community Pharmacy Contractual Framework, which did include material relating to ending Medicines Usage Reviews, is not being published at this time.<\/p>"}
, "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"}
}
, "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"}
, "answeringMemberPrinted" : {"_value" : "Jo Churchill"}
, "dateOfAnswer" : {"_value" : "2019-09-09", "_datatype" : "dateTime"}
, "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"}
, "questionFirstAnswered" : [{"_value" : "2019-09-09T15:26:16.77Z", "_datatype" : "dateTime"}
]}
, "answeringDeptId" : {"_value" : "17"}
, "answeringDeptShortName" : {"_value" : "Health and Social Care"}
, "answeringDeptSortName" : {"_value" : "Health and Social Care"}
, "date" : {"_value" : "2019-09-02", "_datatype" : "dateTime"}
, "hansardHeading" : {"_value" : "NHS: Drugs"}
, "houseId" : {"_value" : "1"}
, "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"}
}
], "questionText" : "To ask the Secretary of State for Health and Social Care, if he will publish the impact assessment for Medicines Usage Reviews not being included in the new community pharmacy contract.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"}
, "tablingMember" : {"_about" : "http://data.parliament.uk/members/4126", "label" : {"_value" : "Biography information for Mary Glindon"}
}
, "tablingMemberConstituency" : {"_value" : "North Tyneside"}
, "tablingMemberPrinted" : [{"_value" : "Mary Glindon"}
], "uin" : "284565"}
], "itemsPerPage" : 10, "page" : 0, "startIndex" : 1, "totalResults" : 9, "type" : ["http://purl.org/linked-data/api/vocab#ListEndpoint", "http://purl.org/linked-data/api/vocab#Page"]}
}